{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:19:56Z","timestamp":1785860396764,"version":"3.56.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Cardiac immune-related adverse events (irAEs) are rare but potentially life-threatening complications of immune checkpoint inhibitor (ICI) therapy, with myocarditis associated with particularly high mortality even under aggressive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 65-year-old male with advanced clear cell renal cell carcinoma and liver metastasis presented with progressive wheezing and fatigue following 4 cycles of combination therapy with toripalimab and axitinib, symptoms that failed to respond to conventional supportive measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Grade 4 ICI-associated myocarditis was confirmed through a combination of clinical manifestations, characteristic echocardiographic abnormalities, elevated cardiac biomarkers, and the exclusion of infectious causes via comprehensive serological evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received multimodal immunosuppressive and supportive therapy, including high-dose methylprednisolone, intravenous immunoglobulin (IVIG), venoarterial extracorporeal membrane oxygenation (VA-ECMO), and therapeutic plasma exchange. Concurrently, broad-spectrum antibiotics were administered based on continuous microbial surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Although transient hemodynamic stabilization was achieved, the patient subsequently developed severe nosocomial infections and progressive multiorgan failure, leading to death on day 24 of hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the necessity for early recognition and intensive monitoring in managing high-grade ICI-associated myocarditis. It further highlights the critical role of infection prevention strategies, particularly the implementation of microbial surveillance-guided antibiotic prophylaxis, in patients undergoing combination immunotherapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary:<\/jats:title>\n                    <jats:p>We report a 65-year-old male with advanced renal cell carcinoma who developed ICI-associated myocarditis following 4 cycles of combination immunotherapy. The patient presented with progressive dyspnea and fatigue, necessitating hospitalization. Comprehensive diagnostic evaluation confirmed grade 4 myocarditis based on clinical features, elevated cardiac biomarkers, echocardiographic abnormalities, and exclusion of infectious causes. Treatment consisted of multimodal immunosuppressive and life-support therapies, including high-dose methylprednisolone, intravenous IVIG, therapeutic plasma exchange, VA-ECMO, and empiric broad-spectrum antibiotics guided by microbial surveillance. Despite transient hemodynamic stabilization, the patient ultimately progressed to multiorgan failure and died on day 24 of hospitalization. This case underscores the life-threatening nature of ICI-associated myocarditis and highlights the critical need for early recognition, aggressive supportive management, and proactive anti-infective prophylaxis in patients receiving combination immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046439","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T21:01:55Z","timestamp":1766782915000},"page":"e46439","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Case report of fatal myocarditis with toripalimab and axitinib combination therapy"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4875-7480","authenticated-orcid":false,"given":"Zhengxin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0261","authenticated-orcid":false,"given":"Chuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"908173","DOI":"10.3389\/fimmu.2022.908173","article-title":"Cardiovascular toxicity with PD-L1\/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval.","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"R3-20251226","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"key":"R4-20251226","doi-asserted-by":"crossref","first-page":"1036603","DOI":"10.3389\/fcvm.2022.1036603","article-title":"Multisystem immune-related adverse events due to toripalimab: two cases-based review.","volume":"9","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"714460","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case report: the neuromusclar triad of immune checkpoint inhibitors: a case report of myositis, myocarditis, and myasthenia gravis overlap following toripalimab treatment.","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R6-20251226","doi-asserted-by":"crossref","first-page":"850540","DOI":"10.3389\/fimmu.2022.850540","article-title":"Anti-GAD65 antibody-associated autoimmune encephalitis with predominant cerebellar involvement following toripalimab treatment: a case report of a novel irAE of toripalimab.","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"824308","DOI":"10.3389\/fonc.2022.824308","article-title":"Case Report: hepatic sarcoid-like reaction associated with checkpoint inhibition in a NSCLC patient and a literature review.","volume":"12","author":"Lin","year":"2022","journal-title":"Front Oncol"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"707967","DOI":"10.3389\/fphar.2021.707967","article-title":"Case report: a case report and literature review on severe bullous skin reaction induced by anti-PD-L1 immunotherapy in a cervical cancer patient.","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"R9-20251226","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CJI.0000000000000484","article-title":"Recurrent cystitis associated with 2 programmed death 1 inhibitors: a rare case report and literature review.","volume":"46","author":"Fan","year":"2023","journal-title":"J Immunother"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/imt-2022-0289","article-title":"Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.","volume":"15","author":"Zhou","year":"2023","journal-title":"Immunotherapy"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"e36998","DOI":"10.1097\/MD.0000000000036998","article-title":"Primary multiple endocrine insufficiency during immune checkpoint inhibitor treatment: a case report.","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor associated myocarditis.","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncol"},{"key":"R13-20251226","doi-asserted-by":"crossref","first-page":"e009364","DOI":"10.1136\/jitc-2024-009364","article-title":"Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.","volume":"13","author":"Nassar","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020.","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R15-20251226","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R16-20251226","doi-asserted-by":"crossref","first-page":"26362648a","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases.","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"issue":"16_suppl","key":"R17-20251226","doi-asserted-by":"crossref","first-page":"e24026","DOI":"10.1200\/JCO.2024.42.16_suppl.e24026","article-title":"Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.","volume":"42","author":"Wu","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:24:15Z","timestamp":1785857055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":17,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046439","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-07-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}